Brand Logo Text

  • For U.S. Residents Only
  • Non–U.S. Residents
 
  • full Prescribing Information
 
  • Home
  • Pa in the lungs in CF
  • About TOBI
    • Effectively fights Pa
    • Minimal Systemic Exposure
    • Safety
    • Dosage and Administration
    • Susceptibility Breakpoints
  • Clinical Benefits
    • Improved FEV1
    • Reduced Hospital Days
    • Reduced Antipseudomonal IV Antibiotics
  • TOBI CARE
  • Resources
  • For Patients
Patient Site
    • Text Bigger
    • Text Smaller
    • Change text size
  • Print this page

SITE MAP

  • Homepage
  • Pa in the Lungs in CF
  • About TOBI
    • Effectively Fights Pa
    • Minimal Systemic Exposure
    • Safety
    • Dosage and Administration
    • Susceptibility Breakpoints
  • Clinical Benefits
    • Improved FEV1
    • Reduced Hospital Days
    • Reduced IV Antipseudomonal Antibiotics
  • TOBI CARE
  • Resources
  • Utility Navigation
    • Important Safety Information
    • Contact Us
    • Site Map
    • Site Guide
    • Terms of Use
    • Privacy Policy
 
  • Home
  • Pa in the lungs in CF
  • About TOBI
  • Clinical Benefits
  • TOBI CARE
  • Resources
  • For Patients
  • Important Safety Information
  • Contact Us
  • Site Guide
  • Site Map
 

Novartis

Use of website is governed by the Terms of Use and Privacy Statement.

Copyright © Novartis Pharmaceuticals Corporation. All rights reserved. Novartis proudly supports the Patient Assistance Now program.

TBI-1013221